Drug Profile
COVI VAC
Alternative Names: 2019-nCoV vaccine - Codagenix/Serum Institute of India; CDX 005; Coronavirus vaccine - Codagenix/Serum Institute of India; COVI-VAC; COVID-19 vaccine - Codagenix/Serum Institute of India; CoviLivTM; SARS-CoV-2 Vaccine - Codagenix/Serum Institute of IndiaLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Codagenix; Serum Institute of India
- Class Antivirals; Attenuated vaccines; COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in United Kingdom (Intranasal)
- 11 Oct 2023 Immunogenicity data from a phase I trial in COVID-2019 infection presented at IDWeek 2023 (IDW-2023)
- 11 Oct 2023 Updated immunogenicity data from a phase I trial in COVID-2019 infection released by Codagenix